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niazid chemoprophylaxis due to resis-
tance of the infecting organism.
Decreased susceptibility to iso-
niazid among M. kansasii isolates is 
common (7,8), and this microorgan-
ism is naturally resistant to pyrazin-
amide (9). This pattern of resistance is 
a serious obstacle for the use of these 
drugs in monotherapy or when com-
bined with rifampin in the prevention 
of lung disease caused by M. kansasii 
(10).
The source of the infection in this 
patient is unknown. In a large series 
of infectious diseases associated with 
inﬂ   iximab therapy, nontuberculous 
mycobacteria were isolated in 9% of 
the patients who had mycobacterial 
diseases (2). As in our patient, these 
infections developed shortly after ini-
tiation of treatment with inﬂ  iximab, 
which suggests that reactivation of a 
latent infection is the most probable 
origin of the disease. Although a mild-
ly positive tuberculin skin test result 
can be observed in patients infected 
with atypical mycobacteria, the strong 
reaction seen in this patient suggests 
a latent infection with M. tuberculosis 
(10). We could speculate on the possi-
bility of a double infection with M. tu-
berculosis (contracted through house-
hold contacts with his father) and M. 
kansasii through environmental expo-
sure. In this scenario, isoniazid che-
moprophylaxis could have prevented 
the former but not the latter.
In summary, failure of isoniazid 
chemoprophylaxis can be anticipated 
in patients who initiate treatment with 
inﬂ   iximab and who have latent in-
fections due to M. kansasii. Despite 
routine antituberculous chemopro-
phylaxis, patients receiving inﬂ  iximab 
therapy should be carefully evaluated 
for lung infection caused by atypical 
mycobacteria. 
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Extensively 
Drug-Resistant 
Mycobacterium 
tuberculosis, India 
To the Editor: India is contrib-
uting nearly one third of the world’s 
tuberculosis (TB) cases and has the 
highest rate of new TB cases (1). 
Prevalence of multidrug-resistant TB 
(MDR TB) cases is on the rise in India, 
and proportions of new cases of MDR 
TB have been observed to vary from 
1.1% to 5.3% in most of the reported 
studies. The proportion of previously 
treated patients with MDR TB varied 
from 8% to 67% (2). Although these 
studies have been conducted in differ-
ent parts of India, they indicate an in-
creasing trend of MDR TB cases.
MDR TB cases threaten the ef-
fectiveness of chemotherapy for both 
treatment and control of TB and re-
quire the use of second-line drugs that 
are more expensive, toxic, and less 
effective than ﬁ  rst-line anti-TB drugs 
(3). The Green Light Committee es-
tablished by the Stop TB partners (4), 
which ensures the proper use of sec-
ond-line drugs to prevent increasing 
drug resistance in MDR TB cases in 
resource-limited countries, encoun-
tered resistance to these drugs. This 
led to the emergence of new termi-
nology in relation to drug-resistant 
TB, i.e., extensively drug-resistant 
TB (XDR TB). XDR TB is deﬁ  ned 
as TB caused by a Mycobacterium tu-
berculosis strain that is resistant to at 
least rifampin and isoniazid among the 
ﬁ  rst-line anti-TB drugs (MDR TB) in 
addition to resistance to any ﬂ  uoroqui-
nolones and at least 1 of 3 injectable 
second-line drugs (5). A recent report 
describes the current prevalence of 
XDR TB worldwide (6). Although In-
dia has high annual risk for TB cases 
and increasing prevalence of MDR TB 
cases, XDR TB has not yet been de-
scribed in India.
From December 2000 through 
December 2002, 68 MDR TB isolates LETTERS
1430  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 13, No. 9, September 2007
were obtained from sputum samples 
from pulmonary TB patients, referred 
to Department of Microbiology, King 
George’s Medical University, Luc-
know Uttar Pradesh, India, for culture 
and sensitivity testing. Drug suscepti-
bility testing for ﬁ  rst-line drugs was 
performed by 1% proportion method 
against streptomycin (4 μg/mL), iso-
niazid (0.2 μg/mL), rifampin (40 μg/
mL), and ethambutol (2 μg/mL) (7). 
The susceptibility of MDR TB isolates 
against second-line drugs was done by 
the absolute concentration method 
(MIC) for oﬂ  oxacin (0.5–16 μg/mL) 
and kanamycin (2–64 μg/mL) and by 
1% proportional sensitivity method 
for ethionamide (40 μg/mL), p-amino 
salicylic acid (0.5 μg/ml), clarithro-
mycin (2 μg/mL), and capreomycin 
(40 μg/mL). Resistance to oﬂ  oxacin, 
kanamycin, and ethionamide was de-
termined by a cut-off of MIC >8 μg/
mL, >64 μg/mL, and >128 μg/mL, 
respectively (8). All drugs were pro-
cured from Sigma (St. Louis, MO, 
USA), and quality control for drug 
susceptibility test was provided by the 
Tuberculosis Research Center, Chen-
nai, India.
Among 68 MDR strains, 21 were 
from patients who had never been 
previously treated, and 47 were from 
patients whose medical history was 
positive for anti-tubercular treatment 
in the past, for at least 4 weeks. All 
MDR TB isolates were tested for 
susceptibility to second-line drugs, 
and high resistance to these drugs 
was found. MDR strains, which were 
further resistant to oﬂ  oxacin, and to 
at least 1 of 2 injectable second-line 
drugs tested (i.e., kanamycin or cap-
reomycin), were classiﬁ   ed as XDR 
TB. A total of 5 (7.4%) of 68 MDR 
TB strains met criteria for XDR TB. 
XDR TB isolates were usually resis-
tant to almost all 4 ﬁ  rst-line and sec-
ond-line anti-TB drugs tested (Table). 
Global data on XDR TB are limited; 
however, a recent article reported that 
the problem of XDR TB is worldwide 
and includes a prevalence of  6.6% 
XDR TB cases in the studied countries 
(6). The Republic of Korea reports the 
maximum numbers of such cases, 
with 200 (15.4%) of 1,298 XDR TB 
strains tested from MDR TB patients 
included in the study. On December 1, 
2006, World AIDS Day, South Africa 
reported >300 cases of XDR TB (9).
Here, we report, to our knowl-
edge, the ﬁ  rst XDR TB cases in India 
and the emergence of XDR TB in set-
tings like India, where adequate moni-
toring of treatment regimens for MDR 
TB in TB control programs is difﬁ  cult 
to implement due to a huge population 
and the high annual risk of acquiring 
TB is of great concern. A limitation to 
accurate detection of XDR TB is those 
existing tests for resistance to second-
line drugs is not yet standardized and is 
less reproducible than results for ﬁ  rst-
line drugs (10). Access to management 
and treatment of MDR TB cases with 
second-line drugs, standardized meth-
ods, improved diagnostics, and qual-
ity assurance for susceptibility testing 
are needed to ensure reliable testing 
and the design of appropriate drug 
regimens.
Our study has some limitations, 
however. The data are not representa-
tive of the whole community and are 
limited to 1 hospital. Limited numbers 
of drugs were used in drug susceptibil-
ity testing, and the sample size is also 
not statistically adequate. A communi-
ty-based, multicenter study, which in-
cludes all parts of the country and uses 
the full spectrum of drugs, is needed to 
describe the true prevalence of XDR 
TB in India.
Rajesh Mondal* and Amita Jain*
*King George’s Medical University, Luc-
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Table. Resistance pattern of XDR TB isolates* 
Strain no.  Resistant to first-line drugs  Resistant to second-line drugs 
RM 55  S, H, R, E K, O, CAP, CLA, PAS, ETH
RM 490  S, H, R, E K, O, CAP, CLA, PAS, ETH
RM 552  S, H, R, E K, O, CAP, CLA, PAS, ETH
RM 585†  S, H, R, E K, O, CLA, PAS, ETH
RM 789  S, H, R, E K, O, CAP, CLA, PAS, ETH
*n = 5; XDR TB, extensively drug-resistant tuberculosis; S, streptomycin; H, isoniazid; R, rifampin; 
E, ethambutol; K, kanamycin; O, ofloxacin; CAP, capreomycin; CLA, clarithromycin; PAS, p–amino 
salicylic acid; ETH, ethionamide. 
†Sensitive to capreomycin. LETTERS
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Stray Dogs and 
Leishmaniasis in 
Urban Areas, 
Portugal
To the Editor: In southern Eu-
rope, zoonotic visceral leishmaniasis 
caused by Leishmania infantum used 
to be considered a rural disease, but 
it is becoming more prevalent in ur-
ban areas. Outbreaks in urban/periur-
ban settings are associated with the 
urbanization of natural zoonotic foci 
(1). The presence of a high number of 
stray dogs in urban/periurban settle-
ments may contribute to the spread 
and increase of new infections. 
A canine survey was performed 
twice a month from December 1, 
2002, through December 31, 2003. A 
total of 374 dogs from urban areas of 
Lisbon were screened for leishmani-
asis. Owners voluntarily brought 277 
domestic dogs; 97 stray dogs were 
from public shelters. Indirect ﬂ  uores-
cent assay was used for detection of 
anti-Leishmania antibodies using a 
cut-off of 1/64, and popliteal lymph 
node aspirates for Novy, Nicolle, and 
MacNeal cultures were tested (2). 
A high overall prevalence (19.2%) 
of canine leishmaniasis was found, 
despite use of conventional tests only. 
The infection rate would probably have 
been higher had more sensitive tech-
niques, such as molecular tools, been 
used. During the 1980s, Abranches et 
al. (2) performed a similar seroepide-
miologic survey and found a preva-
lence rate of 5.5%. 
Our results show an increase of ca-
nine leishmaniasis cases in Lisbon. In 
our study, the prevelance of infection 
in domestic dogs was 18.4% (51/277), 
and the prevelance in stray dogs was 
21.6% (21/97), with no statistical dif-
ference (p = 0.48, signiﬁ  cance level 
95%). These results support the im-
portance of the role of stray dogs in 
parasite transmission in Lisbon but 
differ from the 7.8% seroprevalence 
found in Madrid, where 1,803 stray 
dogs were studied over a 10-year pe-
riod (3). However, the sample size and 
duration of both studies are different. 
In other urban areas of large European 
cities and Brazil, the existence of a 
high canine seroprevalence has shown 
an urbanization of the parasitosis (4,5). 
This is associated with an increase in 
1-family homes with gardens in the 
peripheries of cities. Dogs are com-
monly kept in these gardens, which 
can provide good habitats for sandﬂ  ies. 
On the other hand, the development 
of suburban areas can also lead to an 
increase of solid waste and deﬁ  cient 
sanitary conditions, thus attracting 
infected stray dogs. The difference in 
percentage of domestic dogs (39.21%) 
and stray dogs (28.57%) that appeared 
healthy, although infected, was not 
statistically signiﬁ  cant (p = 0.39). The 
percentage of apparently healthy dogs 
was lower than expected, as different 
studies have shown that more than half 
of the seropositive dogs are asymp-
tomatic (3,6). Moreover, stray dogs 
are more likely to experience deﬁ  cient 
health and nutritional conditions, and 
we thus expected larger differences 
between the 2 groups of animals. Of 
note, asymptomatic infected dogs can 
be a source of infection to the vectors, 
although symptomatic dogs are more 
effective reservoirs (6).
Along with the canine survey, 
from June through September a to-
tal of 488 sandﬂ   ies were collected 
from 99 biotopes selected from the 
studied areas where canine or human 
cases have been diagnosed. The vec-
tors were morphologically identiﬁ  ed 
by standard entomologic keys (7) as 
follows: 392 (80.33%) Phlebotomus  
perniciosus, 93 (19.06%) Ph. ariasi, 
and 3 (0.61%) Ph. sergenti. Phleboto-
mine density ranged from 0.08 to 7.70 
specimens/CDC trap/night. Ph. ariasi 
was found infected, reﬂ  ecting an over-
all infection rate of 1.22 % (1/82).
In Portugal, Ph. ariasi and Ph. 
perniciosus are the proven vectors of 
L. infantum ( 8). Although phleboto-
mine infection was proven in Lisbon, 
it was low when compared with the 
canine infection rate, highlighting 
the need for a more extensive vecto-
rial study in these areas. From 2002 
through 2006, 20 new cases of kala-
azar in immunocompromised patients 
(16 children and 4 adults) were diag-
nosed in our laboratory. In spite of 
the number of new cases being higher 
in immunocompromised persons, 
namely, HIV-infected patients, gener-
ally only the cases of immunocompe-
tent persons reﬂ   ect natural zoonotic 
transmission. Immunocompromised 
patients can also experience the reac-
tivation of an old latent infection or be 
infected by zoonotic transmission or 
by anthroponotic transmission with-
out a vector. Despite some studies that 
have shown a direct relationship be-
tween the prevalence of leishmaniasis 
in canine and human populations, ca-
nine leishmaniasis is much more prev-
alent and more widely distributed than 
visceral leishmaniasis, and it does not 
strongly correlate with the prevalence 
in humans (6). Moreover, Ph. ariasi 
and Ph. perniciosus are known to be 
preferentially zoophilic.
In domestic dogs, if the owner 
takes preventive measures, the infec-
tion risk may be reduced. Stray dogs, 
however, are an easier target for infec-
tion and sandﬂ  y biting due to precari-
ous physical conditions and outdoor 
living habits that make canine leish-
maniasis control much more difﬁ  cult.
In conclusion, sanitary conditions 
and animal health must be improved to 
prevent the transmission risk of leish-
maniasis by this group of animals. The 
absence of surveillance or preventative 
measures and equilibrium rupture in 